Abstinence Tied to Lower Mortality in Alcoholic Cirrhosis With Portal Hypertension
(MedPage Today) -- Alcohol abstinence was associated with improved prognosis across all stages of clinically significant portal hypertension in patients with alcohol-related cirrhosis, according to an observational study. Among 320 such patients... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - December 8, 2022 Category: Gastroenterology Source Type: news

COVID-19 Booster Vaccine Appears Safe for IBD Patients
(MedPage Today) -- ORLANDO, Florida – People with inflammatory bowel disease (IBD) who received a third dose of COVID-19 vaccine – i.e., a booster shot -- did not appear to be at risk of greater adverse events (AEs) than those without... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - December 7, 2022 Category: Gastroenterology Source Type: news

Infliximab Maintenance Home Infusion Appears Safe
(MedPage Today) -- ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher reported here. Of 863 patients... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - December 7, 2022 Category: Gastroenterology Source Type: news

Will Fresh Look at Obeticholic Acid Data in NASH Sway FDA?
(MedPage Today) -- WASHINGTON -- A daily oral dose of obeticholic acid (Ocaliva) led to improvement in liver fibrosis without disease worsening for patients with non-alcoholic steatohepatitis (NASH), and with a good safety profile, according... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 12, 2022 Category: Gastroenterology Source Type: news

Novel Hepatitis B Drug Hints at Long-Term 'Functional Cure' for Some in Early Trial
(MedPage Today) -- WASHINGTON -- Investigational antisense RNA-based therapy bepirovirsen sustained clearance of both hepatitis B virus (HBV) DNA and surface antigen (HBsAg) for a modest proportion of patients out to 6 months after injections... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 11, 2022 Category: Gastroenterology Source Type: news

Efruxifermin Led to NASH Resolution, Fibrosis Improvement in Mid-Stage Trial
(MedPage Today) -- Use of the long-acting FGF21 analog efruxifermin led to statistically significant improvements in fibrosis and resolution of nonalcoholic steatohepatitis (NASH) compared with placebo, the phase IIb randomized HARMONY trial showed... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 10, 2022 Category: Gastroenterology Source Type: news

Odevixibat Shows 'Encouraging Results' for Kids With Alagille Syndrome
(MedPage Today) -- WASHINGTON -- Treatment with odevixibat (Bylvay) led to early, rapid, and sustained improvements in pruritus among pediatric patients with Alagille syndrome, as well as reductions in bile acid levels, the phase III ASSERT trial... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 9, 2022 Category: Gastroenterology Source Type: news

Tenofovir, Vaccine Combo Eliminates Mom-to-Child HBV Transmission
(MedPage Today) -- Earlier maternal tenofovir disoproxil fumarate (TDF) combined with infant vaccination completely eliminated vertical transmission of chronic hepatitis B virus (HBV) from highly viremic mothers, even without the use of hepatitis... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 8, 2022 Category: Gastroenterology Source Type: news

A Fork in the Road on My 'Cancer Journey'
(MedPage Today) -- For the past 12 years, I have been focused on my diagnosis of low-risk prostate cancer, and in 2016, I began sharing my experience and covering the latest developments in the field in my "A Patient's Journey" blog for MedPage... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 7, 2022 Category: Gastroenterology Source Type: news

Earlier Terlipressin May Be Better for HRS-AKI in Acute-on-Chronic Liver Failure
(MedPage Today) -- Starting terlipressin (Terlivaz) well before the 48-hour period to establish a diagnosis of hepatorenal syndrome acute kidney injury (HRS-AKI) led to better outcomes for patients with acute-on-chronic liver failure (ACLF), according... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 7, 2022 Category: Gastroenterology Source Type: news

FDA Rejects Hep D Drug; Cash for Colonoscopies; Mortality in MAFLD Without Obesity
(MedPage Today) -- The FDA rejected Gilead's first-in-class entry inhibitor, bulevirtide, for treating adults with hepatitis delta virus, citing manufacturing and delivery concerns, the company said. Meanwhile, the agency expanded the indication... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 3, 2022 Category: Gastroenterology Source Type: news

One in Eight U.S. Adult Deaths Involved Too Much Booze
(MedPage Today) -- One out of every eight deaths in Americans ages 20 to 64 resulted from drinking too much alcohol, according to a U.S. population-based study. Nationally, 12.9% of total deaths per year among adults in this age group were attributed... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 1, 2022 Category: Gastroenterology Source Type: news

Continuing Ozanimod Prevented More Relapses in Ulcerative Colitis
(MedPage Today) -- Ulcerative colitis relapses in patients with moderate-to-severe disease were seen as early as 8 weeks among responders who stopped ozanimod (Zeposia) after induction therapy, a post-hoc analysis of the phase III True North study... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 28, 2022 Category: Gastroenterology Source Type: news

Oral Microbiome Therapy Tied to Low Recurrence of C. Diff
(MedPage Today) -- A potential first-in-class investigational microbiome therapeutic, SER-109, was safe and observed to sustain low Clostridioides difficile (C. diff) recurrence rates for adults, according to the phase III, single-arm ECOSPOR IV... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 28, 2022 Category: Gastroenterology Source Type: news

Upadacitinib Maintenance Triples Clinical Remissions in Crohn's Disease
(MedPage Today) -- Depending on the dose, maintenance upadacitinib (Rinvoq) either doubled or tripled clinical remissions at 1 year in patients with moderately to severely active Crohn's disease, the phase III U-ENDURE trial showed. In an intention... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 27, 2022 Category: Gastroenterology Source Type: news